TNFRSF17 and systemic lupus erythematosus: In addition, we recently utilized the CD3-BCMA bispecific antibody teclistamab, approved for multiple myeloma [9], in a refractory case of SLE, which resulted in a complete clinical and serologic remission despite the discontinuation of immunosuppressive therapies.